echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Genting Xinyao Trodelvy Approved in Singapore for Second-Line Treatment of Metastatic Triple-Negative Breast Cancer

    Genting Xinyao Trodelvy Approved in Singapore for Second-Line Treatment of Metastatic Triple-Negative Breast Cancer

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 7, Genting Sunyao announced that the Singapore Health Sciences Authority (HSA) has approved Trodelvy® (gosatuzumab) for the treatment of patients who have received at least two prior systemic therapies (at least one of which is for metastatic disease).


    In addition to Singapore, the relevant regulatory agencies in Greater China and South Korea have accepted relevant review applications for Trodelvy for the treatment of unresectable patients who have received at least two prior systemic therapies, at least one of which is for metastatic disease.


    In May 2021, China's National Medical Products Administration accepted Trodelvy's biological product marketing authorization application and granted priority review


    In December 2021, the Korean Ministry of Food and Drug Safety (MFDS) accepted the new drug application for Trodelvy


    In December 2021, the Taiwan Food and Drug Administration accepted the new drug marketing application for Trodelvy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.